Osteosarcoma metastatic

3 trials MedDRA PT
3 Registered trials
0 Recruiting
3 Unique sponsors
2 Unique IMPs
0 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
RAF/BRAF inhibitor 1 substance
Unknown / small molecule 1 substance
Phase II: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

3 trials
  • Instytut Matki I Dziecka Academic
    IMP not specified
    2024-514720-17-00 1 country 2022 n=30
    Ended
  • Unicancer Academic
    REGORAFENIB
    2024-513455-33-00 1 country 2014 n=159
    Ended
  • Vall D Hebron Institute Of Oncology Academic
    OMO-103
    2024-510987-22-00 1 country 2024 n=10
    Halted
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Instytut Matki I Dziecka Academic 1 Phase II 0
Unicancer Academic 1 Phase II 0
Vall D Hebron Institute Of Oncology Academic 1 Phase II 0
New trials by year
2022
1
2024
1
← All indication landscapes